Second line therapy in type 2 diabetes: legacy effect activation
Type 2 diabetes causes hundred thousand deaths worldwide every year. Though new antidiabetic drugs appear annually and new classes of drugs are invented approximately every ten years still a lot of type 2 diabetic patients remain to be out of the target glycemic levels. According to most of the gui...
Guardado en:
Autor principal: | Ekaterina A. Shestakova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/effa23afa59d45be871c37adb10145d3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010) -
Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018) -
Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019) -
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
por: Elena V. Biryukova
Publicado: (2019)